ROCKLAND IMMUNOCHEMICALS, INC.

Address

PO BOX 5199, 321 JONES BLVD
LIMERICK, PA 19468-5199
POTTSTOWN, PA, 19464-3468

Information

DUNS: 058999129
# of Employees: 0

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. IGF OT IGF SYSTEMIC PRE TARGETED RADIOIMMUNOTHERAPY WITH BISPECIFIC NANOBODIES FOR CANCER TREATMENT

    Amount: $299,625.00

    ABSTRACT Radioimmunotherapy RIT targeting of cancer is limited by slow blood clearance resulting in unwanted prolonged exposure of normal tissues to radioactive agents Pre targeted radioimmunother ...

    SBIRPhase I2016Department of Health and Human Services
  2. Synthetic antibodies for monitoring modified RNAs

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in t ...

    SBIRPhase I2014Department of Health and Human Services
  3. Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings

    Amount: $489,072.00

    DESCRIPTION provided by applicant Hemoglobinopathies are the most common monogenic diseases with approximately of the worldandapos s population being carriers Sickle cell disease SCD and tha ...

    SBIRPhase I2014Department of Health and Human Services
  4. TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

    Amount: $249,975.00

    Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop nove ...

    SBIRPhase I2013Department of Health and Human Services
  5. TAS::75 0849::TAS SBIR TOPIC 292 PHASE I DEVELOPMENT OF MOLECULAR PHARMACODYNAMIC ASSAYS FOR TARGETED THERAPIES

    Amount: $149,866.00

    The RON and c-MET signal pathways are critical regulators of cell growth, survival, migration, differentiation, and drug resistance. High levels of activated RON or c-MET have been observed in a numbe ...

    SBIRPhase I2011Department of Health and Human Services
  6. SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MTOR INHIBITORS

    Amount: $999,002.00

    In response to this NCI solicitation, Rockland proposes to develop a novel method to assay the pharmacodynamic (PO) properties of anti-cancer small molecules targeting the PI3K/mTOR/AKT signaling path ...

    SBIRPhase II2011Department of Health and Human Services
  7. MULTIPLEXED ASSAYS FOR AKT/M TOR PATHWAY- PHASE I SBIR TOPIC

    Amount: $149,937.00

    PTEN/Akt/mTORC 1and2 signal pathway is a critical regulator of cell survival, cell growth and proliferation, angiogenesis, cellular metabolism, cell migration and invasion and glucose uptake. A number ...

    SBIRPhase I2010Department of Health and Human Services
  8. Not Available

    Amount: $299,954.00

    Antibody therapy offers treatment for a wide range of diseases and can extend the life of cancer patients, but the treatment cost is extremely expensive. as patent protection of some current antibodie ...

    SBIRPhase I2010Department of Health and Human Services
  9. Novel Point-of-Care Multiplex Lyme Disease Test

    Amount: $315,172.00

    DESCRIPTION (provided by applicant): Lyme disease (LD) is caused by spirochetal bacteria from the genus Borrelia. Borrelia burgdorferi is the predominant cause of Lyme disease in the United States, wh ...

    SBIRPhase I2009Department of Health and Human Services
  10. PHARMACODYNAMIC ASSAYS FOR TARGETED THERAPIES

    Amount: $149,970.00

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government